BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 36759723)

  • 1. The oncogenic roles and clinical implications of YAP/TAZ in breast cancer.
    Luo J; Zou H; Guo Y; Tong T; Chen Y; Xiao Y; Pan Y; Li P
    Br J Cancer; 2023 May; 128(9):1611-1624. PubMed ID: 36759723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into the ambivalent role of YAP/TAZ in human cancers.
    Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
    J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into recent findings and clinical application of YAP and TAZ in cancer.
    Franklin JM; Wu Z; Guan KL
    Nat Rev Cancer; 2023 Aug; 23(8):512-525. PubMed ID: 37308716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises.
    Ortega Á; Vera I; Diaz MP; Navarro C; Rojas M; Torres W; Parra H; Salazar J; De Sanctis JB; Bermúdez V
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
    Nishina H
    Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
    Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
    Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers.
    Howard A; Bojko J; Flynn B; Bowen S; Jungwirth U; Walko G
    Exp Dermatol; 2022 Oct; 31(10):1477-1499. PubMed ID: 35913427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YAP/TAZ at the Roots of Cancer.
    Zanconato F; Cordenonsi M; Piccolo S
    Cancer Cell; 2016 Jun; 29(6):783-803. PubMed ID: 27300434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
    Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
    J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.
    Kim MH; Kim J
    Cell Mol Life Sci; 2017 Apr; 74(8):1457-1474. PubMed ID: 27826640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K Positively Regulates YAP and TAZ in Mammary Tumorigenesis Through Multiple Signaling Pathways.
    Zhao Y; Montminy T; Azad T; Lightbody E; Hao Y; SenGupta S; Asselin E; Nicol C; Yang X
    Mol Cancer Res; 2018 Jun; 16(6):1046-1058. PubMed ID: 29545474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Context-dependent transcriptional regulations of YAP/TAZ in stem cell and differentiation.
    Luo J; Li P
    Stem Cell Res Ther; 2022 Jan; 13(1):10. PubMed ID: 35012640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging roles for the YAP/TAZ transcriptional regulators in brain tumour pathology and targeting options.
    Strepkos D; Markouli M; Papavassiliou KA; Papavassiliou AG; Piperi C
    Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12762. PubMed ID: 34409639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity.
    Yuan B; Liu J; Shi A; Cao J; Yu Y; Zhu Y; Zhang C; Qiu Y; Luo H; Shi J; Cao X; Xu P; Shen L; Liang T; Zhao B; Feng XH
    EMBO J; 2023 Feb; 42(4):e111549. PubMed ID: 36598329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yes-Associated Protein and Transcriptional Coactivator with PDZ-Binding Motif in Cardiovascular Diseases.
    Li R; Huang W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of YAP/TAZ in ferroptosis.
    Magesh S; Cai D
    Trends Cell Biol; 2022 Sep; 32(9):729-732. PubMed ID: 35701310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells.
    Fu J; Liu W; Liu S; Zhao R; Hayashi T; Zhao H; Xiang Y; Mizuno K; Hattori S; Fujisaki H; Ikejima T
    Cell Signal; 2024 Jul; 119():111186. PubMed ID: 38643945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCM3 is a gatekeeper in focal adhesions regulating mechanotransduction and YAP/TAZ signalling.
    Wang S; Englund E; Kjellman P; Li Z; Ahnlide JK; Rodriguez-Cupello C; Saggioro M; Kanzaki R; Pietras K; Lindgren D; Axelson H; Prinz CN; Swaminathan V; Madsen CD
    Nat Cell Biol; 2021 Jul; 23(7):758-770. PubMed ID: 34226698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.